ClinicalTrials.gg
CompletedNCT01183650Updated May 16, 2012Results posted

A Study of Tadalafil in Benign Prostatic Hyperplasia

A Phase 1 interventional study of Tadalafil in Benign Prostatic Hyperplasia, sponsored by Eli Lilly and Company. Completed at 1 site in Germany. Open to male participants aged 45 Years and older. Per ClinicalTrials.gov, last updated 2012-05-16.

Sponsored by Eli Lilly and Company · Phase 1, Interventional, and Basic science

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
24
Ages
45 Years and older
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 26 studies testing tadalafil in Prostatic Hyperplasia — 2 open to participants now, 2 under way, none of them phase 3. Tadalafil · Prostatic Hyperplasia.

Enrollment
26th of 26
24 · median 258
Started
2010
with 2 others
Phase 1
5 of 26
1 open now
Registered
13th of 26
by date
Lead sponsor
16 of 26
Eli Lilly and Company

Among the 26 studies testing tadalafil in Prostatic Hyperplasia, this one is the 26th largest by enrollment, is one of 3 that started in 2010, is one of 5 in phase 1, and was the 13th registered.

Prostatic Hyperplasia

828 studies on the registry are indexed under Prostatic Hyperplasia; 179 are open to participants now.

Browse Prostatic Hyperplasia studies →

Open to participants now

2 of the 26 studies testing tadalafil in Prostatic Hyperplasia are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About tadalafil

Tadalafil: first FDA approval 2003 (CIALIS), first EMA approval 2002. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 102 Prostatic Hyperplasia studies recruiting now, 70 (69%) set no upper age limit and 4 (4%) stop at 75 or younger; 7 take children under 18; 7 take healthy volunteers.

This study: 45 Years and older · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 26 studies testing tadalafil in Prostatic Hyperplasia, or all of them as a file.
02

Study summary

The purpose of this study is to investigate the pharmacokinetics of tadalafil in Japanese and non-Japanese men with Benign Prostatic Hyperplasia (BPH).

The safety of tadalafil will also be studied.

03

Conditions studied

  • Benign Prostatic Hyperplasia

Browse trials for

04

Who can participate

Ages eligible
45 Years and older
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Have had lower urinary tract symptoms secondary to benign prostatic hyperplasia (BPH-LUTS) (as diagnosed by a qualified physician) >6 months at screening visit. Lower urinary tract symptoms (LUTS) include those associated with voiding (obstructive symptoms, such as incomplete emptying, intermittency, weak stream, straining) and/or storage (irritative symptoms, such as frequency, urgency, nocturia).
  • Have BPH-LUTS with moderate-to-severe symptoms confirmed by an International Prostate Symptom Score (IPSS) >12. (The IPSS total score is defined as the sum of Questions 1 through 7 and does not include the IPSS Quality of Life.)
  • Taking into account the age and disease status, subjects determined to be in good health according to medical history, physical examination, (ECG), and laboratory safety assessments.
  • between 18 and 30 kg/m\^2 inclusive.
  • Agree not to use any other approved or experimental pharmacologic BPH, erectile dysfunction (ED), and/or overactive bladder (OAB) treatments, including alpha blockers, phosphodiesterase type 5 (PDE5) inhibitors, or herbal preparations at least 1 week prior to dosing and through to follow-up.
  • Subjects with a serum prostate-specific antigen (PSA) \<10.0 ng/mL. Subjects with a serum PSA greater than or equal to 4.0 and \<10.0 ng/mL must have documentation of a negative histologic of carcinoma of the prostate within 12 months prior to screening.

Exclusion criteria

Exclusion Criteria:

  • History of radical prostatectomy, or other pelvic surgery or procedure, including any pelvic surgical procedure on the urinary tract apart from transurethral resection, pelvic surgery for or bowel resection, or a history of lower urinary tract malignancy or trauma. History of urinary retention or lower urinary tract (bladder) stones within 6 months of screening.
  • Current or previous history of malignant disease of the prostate.
  • Concomitant treatment with or ingestion of cytochrome P 450 3A4 ()-inducing or -inhibiting agents from 2 weeks prior to dosing and through the end of the study. Including herbal/food and other supplements, fruit, or fruit juices containing grapefruit or pomegranate components.
  • History of loss of vision in one eye because of nonarteritic anterior ischemic optic neuropathy (NAION), regardless of whether this episode was in connection or not with previous PDE5 inhibitor exposure.
  • Subjects with chronic stable angina treated with long-acting nitrates, subjects with chronic stable angina who required short-acting nitrates in the 90 days prior to screening visit, or subjects with angina occurring during sexual intercourse in the 6 months prior to screening.
  • Subjects having met the criteria for unstable angina within 6 months prior to screening, history of myocardial infarction or coronary artery bypass graft surgery within 90 days prior to screening, or percutaneous coronary intervention (for example, angioplasty or stent placement) within 90 days prior to screening.
  • Any evidence of heart disease ( [NYHA] greater than or equal to Class III) within 6 months of screening.
  • A history of cardiac arrest.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
24 participants (actual)

Study arms

  • Experimental
    Tadalafil

    5 mg, administered orally, daily for 10 days

    Drug: Tadalafil

Interventions

  • 5 mg, administered orally, daily for 10 days

    Also known as: LY450190, Cialis, Adcirca

06

What researchers measure

Primary outcomes

  1. Pharmacokinetics: Area Under the Concentration Curve (AUC) for Tadalafil and Metabolite IC710

    AUC for Day 1 is reported as AUC(tau \[t\], day 1), which is AUC from time zero to 24 hours (t) postdose on Day 1. AUC for Day 10 is reported as AUC(t,steady state \[ss\]), which is AUC during one 24-hour dosing interval at steady-state.

    Time frame: 1 day and 10 days

  2. Pharmacokinetics: Concentration Maximum (Cmax) of Tadalafil and Metabolite IC710

    Time frame: 1 day and 10 days

  3. Pharmacokinetics: Time to Concentration Maximum (Tmax) of Tadalafil and Metabolite IC710

    Time frame: 1 day and 10 days

07

Results

Posted May 16, 2012

Participant flow

Participant flow — Overall Study
MilestoneJapanese ParticipantsCaucasian Participants
Started1212
Completed1212
Not completed00

Outcome measures

PrimaryPharmacokinetics: Area Under the Concentration Curve (AUC) for Tadalafil and Metabolite IC710

AUC for Day 1 is reported as AUC(tau \[t\], day 1), which is AUC from time zero to 24 hours (t) postdose on Day 1. AUC for Day 10 is reported as AUC(t,steady state \[ss\]), which is AUC during one 24-hour dosing interval at steady-state.

Time frame:
1 day and 10 days
Reported as:
Geometric mean · nanograms*hour/milliliter (ng*hr/mL)
Pharmacokinetics: Area Under the Concentration Curve (AUC) for Tadalafil and Metabolite IC710
nanograms*hour/milliliter (ng*hr/mL)Japanese ParticipantsCaucasian Participants
Day 1 Tadalafil1410 ± 311340 ± 17
Day 10 Tadalafil2710 ± 273410 ± 51
Day 1 Metabolite IC710525 ± 27399 ± 23
Day 10 Metabolite IC7102270 ± 302290 ± 48
Statistical analysis
  • Japanese Participants vs Caucasian Participants · Ratio of geometric least squares means: 1.05 · 90% CI 0.84 to 1.32Day 1 Tadalafil Ratio of Geometric Least Squares Means (Japanese/Caucasian)
  • Japanese Participants vs Caucasian Participants · Ratio of geometric least squares means: 0.80 · 90% CI 0.64 to 1.00Day 10 Tadalafil Ratio of Geometric Least Squares Means (Japanese/Caucasian)
  • Japanese Participants vs Caucasian Participants · Ratio of geometric least squares means: 1.31 · 90% CI 1.05 to 1.64Day 1 Metabolite IC710 Ratio of Geometric Least Squares Means (Japanese/Caucasian)
  • Japanese Participants vs Caucasian Participants · Ratio of geometric least squares means: 0.99 · 90% CI 0.79 to 1.24Day 10 Metabolite IC710 Ratio of Geometric Least Squares Means (Japanese/Caucasian)
PrimaryPharmacokinetics: Concentration Maximum (Cmax) of Tadalafil and Metabolite IC710
Time frame:
1 day and 10 days
Reported as:
Geometric mean · nanograms per milliliter (ng/mL)
Pharmacokinetics: Concentration Maximum (Cmax) of Tadalafil and Metabolite IC710
nanograms per milliliter (ng/mL)Japanese ParticipantsCaucasian Participants
Day 1 Tadalafil102 ± 27104 ± 19
Day 10 Tadalafil173 ± 24215 ± 36
Day 1 Metabolite IC71032.1 ± 2524.0 ± 26
Day 10 Metabolite IC710105 ± 31102 ± 47
Statistical analysis
  • Japanese Participants vs Caucasian Participants · Ratio of geometric least squares means: 0.98 · 90% CI 0.81 to 1.18Day 1 Tadalafil Ratio of Geometric Least Squares Means(Japanese/Caucasian)
  • Japanese Participants vs Caucasian Participants · Ratio of geometric least squares means: 0.81 · 90% CI 0.67 to 0.97Day 10 Tadalafil Ratio of Geometric Least Squares Means (Japanese/Caucasian)
  • Japanese Participants vs Caucasian Participants · Ratio of geometric least squares mean: 1.33 · 90% CI 1.07 to 1.67Day 1 Metabolite IC710 Ratio of Geometric Least Squares Means (Japanese/Caucasian)
  • Japanese Participants vs Caucasian Participants · Ratio of geometric least squares means: 1.03 · 90% CI 0.83 to 1.29Day 10 Metabolite IC710 Ratio of Geometric Least Squares Means (Japanese/Caucasian)
PrimaryPharmacokinetics: Time to Concentration Maximum (Tmax) of Tadalafil and Metabolite IC710
Time frame:
1 day and 10 days
Reported as:
Median · hours
Pharmacokinetics: Time to Concentration Maximum (Tmax) of Tadalafil and Metabolite IC710
hoursJapanese ParticipantsCaucasian Participants
Day 1 Tadalafil4.00 (1.00 to 4.00)2.00 (1.00 to 4.00)
Day 10 Tadalafil3.00 (2.00 to 4.00)2.53 (1.00 to 4.00)
Day 1 Metabolite IC71023.83 (23.83 to 23.83)24.00 (16.02 to 24.03)
Day 10 Metabolite IC7104.00 (0.00 to 24.00)8.00 (0.00 to 24.00)
Statistical analysis
  • Japanese Participants · Wilcoxon (Mann-Whitney) · Median difference (final values): 0.00Tadalafil Median Difference (Day 1 - Day 10) in Japanese Participants
  • Caucasian Participants · Wilcoxon (Mann-Whitney) · Median difference (final values): 0.00Tadalafil Median Difference (Day 1 - Day 10) in Caucasian Participants
  • Japanese Participants · Wilcoxon (Mann-Whitney) · Median difference (final values): 19.83Metabolite IC710 Median Difference (Day 1 - Day 10) in Japanese participants
  • Caucasian Participants · Wilcoxon (Mann-Whitney) · Mean difference (final values): 16.02Metabolite IC710 Median Difference (Day 1 - Day 10) in Caucasian participants

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Japanese Participants—0/12 (0%)0/12 (0%)
Caucasian Participants—0/12 (0%)12/12 (100%)
Most frequent other events
Showing 10 of 20
Most frequent other events
EventJapanese ParticipantsCaucasian Participants
HeadacheNervous system disorders0/124/12
MyalgiaMusculoskeletal and connective tissue disorders0/123/12
Pain in extremityMusculoskeletal and connective tissue disorders0/123/12
DyspepsiaGastrointestinal disorders0/122/12
FlatulenceGastrointestinal disorders0/122/12
DizzinessNervous system disorders0/122/12
Abdominal painGastrointestinal disorders0/121/12
Bowel movement irregularityGastrointestinal disorders0/121/12
DiarrhoeaGastrointestinal disorders0/121/12
Dry mouthGastrointestinal disorders0/121/12

Baseline characteristics

Age Continuous
Age Continuous(years)Japanese ParticipantsCaucasian ParticipantsTotal
Mean57.0 ± 9.960.6 ± 7.258.8 ± 8.7
Sex: Female, Male
Sex: Female, Male(Participants)Japanese ParticipantsCaucasian ParticipantsTotal
Female000
Male121224
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Japanese ParticipantsCaucasian ParticipantsTotal
Hispanic or Latino000
Not Hispanic or Latino121224
Unknown or Not Reported000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Japanese ParticipantsCaucasian ParticipantsTotal
American Indian or Alaska Native000
Asian12012
Native Hawaiian or Other Pacific Islander000
Black or African American000
White01212
More than one race000
Unknown or Not Reported000
Region of Enrollment
Region of Enrollment(participants)Japanese ParticipantsCaucasian ParticipantsTotal
Germany01212
Japan12012
08

Study locations

1 site
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Munich, 80636, Germany
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jul 2010, a primary completion of Apr 2011 and a completion of Apr 2011. It does not say whether these dates are actual or estimated.

Results were first posted in May 2012, 1 year 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 13, 2010
First posted
Aug 17, 2010
Start
Jul 2010
Primary completionActual
Apr 2011
CompletionActual
Apr 2011
Results first posted
May 16, 2012
Last update
May 16, 2012
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 16, 2012, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01183650
Responsible party
Sponsor
First posted
Aug 17, 2010
Start date
Jul 2010
Primary completion
Apr 2011
Completion
Apr 2011
Results posted
May 16, 2012
Last update
May 16, 2012

Study contacts

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
study director · Eli Lilly and Company

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2012. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tadalafil

Start the discussion